The GLP-1 agonist market is expected to increase in the coming years due to the emergence of new treatment options, expected launch of potential therapies such as Orforglipron, Survodutide, Retatrutide, Tirzepatide, Semaglutide, AMG-133, VK-2735, and others in the market during the…
